Corbus Pharmaceuticals (CRBP) announced data from its Phase 1/2 clinical study of CRB-701 will be presented as a poster at the 2025 European Society for Medical Oncology, ESMO25, Congress being held in Berlin, Germany. The poster titled, “Phase 1/2 study of the next-generation Nectin-4-targeting antibody-drug conjugate CRB-701 in patients with urothelial and non-urothelial solid tumors” by Perez et al will be presented tomorrow, October 19, 2025, from 12:00-12:45 CEST. Data as of September 1, 2025 will be presented from 167 patients, of whom 1221 were evaluable for efficacy. The tumor types being investigated were head and neck squamous cell carcinoma, cervical cancer and locally advanced/metastatic urothelial tumors. In addition, 21 patients who had other solid-tumor types were enrolled during dose escalation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals’ Promising CRB-701 Trial and Strategic Investor Engagement Justify Buy Rating
- Corbus Pharmaceuticals to present CRB-701 Phase 1/2 data at ESMO 2025
- Optimistic Buy Rating for Corbus Pharmaceuticals Ahead of Promising CRB-701 Trial Results
- Why Are Cannabis Stocks Up Today?
- Corbus Pharmaceuticals’ CRB-701: A Promising Investment with FDA Fast Track and ESMO 2025 Insights